Inebilizumab API is a pharmaceutical-grade humanized anti-CD19 monoclonal antibody developed for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive. It selectively binds to the CD19 antigen expressed on B lymphocytes, resulting in targeted depletion of B cells that contribute to autoimmune disease progression.
By reducing pathogenic B-cell populations, Inebilizumab helps decrease relapse rates and neurological damage associated with autoimmune disorders. It is formulated as an intravenous injectable biologic and represents an important advancement in targeted immunotherapy.
Manufactured under WHO-GMP-certified biopharmaceutical facilities, our Inebilizumab API is produced using advanced recombinant biotechnology to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Each batch is supplied with comprehensive documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Inebilizumab API is used in injectable biopharmaceutical formulations for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) and related autoimmune disorders.
Inebilizumab binds to the CD19 antigen on B lymphocytes, leading to targeted depletion of pathogenic B cells involved in autoimmune disease progression.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Inebilizumab API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing with worldwide export support.
Get Bulk Quote via WhatsApp